Paul Fields

Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity

Yamuna Devi Paila, Rolando Pajón, Barbara L. Banbury, Paul Fields et autres

Cell-mediated immunity contributes to durable protection against severe COVID-19, particularly as antibody responses wane or viral variants partially evade neutralization. Here, we characterize SARS-CoV-2-specific T cell responses elicited by a next-generation COVID-19 vaccine, mRNA-1283, which encodes the receptor-binding and N-terminal domains of …

us (code pays fourni par la source)

Pre-transplant T-cell clonal analysis identifies CD8+ donor reactive clones that contribute to kidney transplant rejection

Jes M. Sanders, Barbara L. Banbury, Jie He, Yuvaraj Sambandam et autres

Introduction Responses to allogeneic human leukocyte antigen (HLA) molecules limit the survival of transplanted organs. The changes in T-cell alloreactivity that contribute to this process, however, are not fully understood. We defined a set of donor reactive T-cell clones (DRTC) with the …

us (code pays fourni par la source)

Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels

Thomas M. Snyder, Rachel M. Gittelman, Mark R. Klinger, Damon May et autres

Introduction: T cells are involved in the early identification and clearance of viral infections and also support the development of antibodies by B cells. This central role for T cells makes them a desirable target for assessing the immune response to SARS-CoV-2 …

us, it (code pays fourni par la source)

COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort

Kristin Raphel, Lafleur J.E., Baric R.S, Ahmed Allabban et autres

The recommended COVID-19 booster vaccine uptake is low. At-home lateral flow assay (LFA) antigen tests are widely accepted for detecting infection during the pandemic. Here, we present the feasibility and potential benefits of using LFA-based antibody tests as a means for individuals …

us (code pays fourni par la source)

COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort

Michael L. Mallory, Jennifer E. Munt, Tara M. Narowski, Izabella N. Castillo et autres

The recommended COVID-19 booster vaccine uptake is low. At-home lateral flow assay (LFA) antigen tests are widely accepted for detecting infection during the pandemic. Here, we present the feasibility and potential benefits of using LFA-based antibody tests as a means for individuals …

us (code pays fourni par la source)

Supplementary Table S4 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Steffan T. Nawrocki, Julian Olea, Claudia Villa Celi, Homa Dadrastoussi et autres

Supplementary Table 4. Distance from tumor cell to immune cell for each patient (Figure 5C)

Supplementary Table S3 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Steffan T. Nawrocki, Julian Olea, Claudia Villa Celi, Homa Dadrastoussi et autres

Supplementary Table 3. Toxicity summary excluding toxicities defined as unrelated to either bortezomib or pelareorep

Supplementary Figure S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Steffan T. Nawrocki, Julian Olea, Claudia Villa Celi, Homa Dadrastoussi et autres

Supplementary Figure 1. Induced expression of cytokines, CD69 in lymphocytes, and PD-L1 in MM cells with no changes in T cell clonality

Supplementary Table S5 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Steffan T. Nawrocki, Julian Olea, Claudia Villa Celi, Homa Dadrastoussi et autres

Supplementary Table 5. Distance from tumor cell to immune cell for each patient (Figure 5E)

Supplementary Figure S2 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Steffan T. Nawrocki, Julian Olea, Claudia Villa Celi, Homa Dadrastoussi et autres

Supplementary Figure 2. TCR analysis

Supplementary Table S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Steffan T. Nawrocki, Julian Olea, Claudia Villa Celi, Homa Dadrastoussi et autres

Supplementary Table 1. Detailed IMC panel

Supplementary Methods S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Steffan T. Nawrocki, Julian Olea, Claudia Villa Celi, Homa Dadrastoussi et autres

Supplementary Methods